September 9, 2021, Montréal – The Canadian Hemophilia Society (CHS) was informed late yesterday by Canadian Blood Services (CBS) that access to Hemlibra (emicizumab) will be expanded to include all those with severe hemophilia A (less than 1% FVIII) without inhibitors, with no age restrictions. CBS procures and distributes coagulation products, including Hemlibra to all provinces and territories except Quebec.
Certain details need to be finalized with the manufacturer, Roche. It is expected that Hemlibra will be available in hemophilia clinics in mid-October.
The listing of Hemlibra on the Héma-Québec formulary was announced in August, though there is no firm date for availability and access criteria remain to be clarified.
On behalf of the hemophilia A community, the CHS would like to thank all those who lent their voices to our efforts to add this innovative therapy to the range of FVIII coagulation products.
